Partners Capital Investment Group’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,448,654
| Closed | -$1.2M | – | 176 |
|
|
2025
Q1 | $1.2M | Buy |
1,448,654
+921,154
| +175% | +$887K | 0.02% | 135 |
|
|
2024
Q4 | $501K | Sell |
527,500
-1,084,012
| -67% | -$1.02M | 0.01% | 115 |
|
|
2024
Q3 | $1.61M | Sell |
1,611,512
-54,285
| -3% | -$60.1K | 0.03% | 127 |
|
|
2024
Q2 | $2.04M | Buy |
1,665,797
+1,138,297
| +216% | +$1.16M | 0.03% | 129 |
|
|
2024
Q1 | $686K | Sell |
527,500
-1,138,297
| -68% | -$1.3M | 0.02% | 123 |
|
|
2023
Q4 | $2.08M | Hold |
1,665,797
| – | – | 0.05% | 122 |
|
|
2023
Q3 | $2.17M | Hold |
1,665,797
| – | – | 0.05% | 119 |
|
|
2023
Q2 | $2.87M | Buy |
1,665,797
+1,138,297
| +216% | +$1.81M | 0.06% | 118 |
|
|
2023
Q1 | $770K | Hold |
527,500
| – | – | 0.03% | 106 |
|
|
2022
Q4 | $855K | Hold |
527,500
| – | – | 0.04% | 106 |
|
|
2022
Q3 | $1.77M | Hold |
527,500
| – | – | 0.1% | 92 |
|
|
2022
Q2 | $1.92M | Hold |
527,500
| – | – | 0.13% | 85 |
|
|
2022
Q1 | $3.81M | Hold |
527,500
| – | – | 0.19% | 76 |
|
|
2021
Q4 | $7.17M | Hold |
527,500
| – | – | 0.33% | 64 |
|
|
2021
Q3 | $11.1M | Hold |
527,500
| – | – | 0.51% | 56 |
|
|
2021
Q2 | $12.6M | Hold |
527,500
| – | – | 0.56% | 53 |
|
|
2021
Q1 | $15.4M | Hold |
527,500
| – | – | 0.68% | 48 |
|
|
2020
Q4 | $15.8M | Buy |
+527,500
| New | +$16.5M | 0.9% | 48 |
|
Partners Capital Investment Group's KRON Position: Q2 2025 in Review
Partners Capital Investment Group sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 1,448,654 shares — an estimated $1.2M sold.
Partners Capital Investment Group first reported a position in KRON in Q4 2020 and held it in 18 quarters. The position peaked at $15.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Partners Capital Investment Group reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Partners Capital Investment Group sold 1,448,654 Kronos Bio shares in Q2 2025, an estimated $1.2M.
- Partners Capital Investment Group first reported a position in Kronos Bio in Q4 2020 and held it in 18 quarters.
- Partners Capital Investment Group's Kronos Bio position peaked at $15.8M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Partners Capital Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.